The End Of Matinas BioPharma Holdings Inc. (NYSE MKT:MTNB)’s trend?

850

Matinas BioPharma Holdings Inc. (NYSE MKT:MTNB)‘s sales surged 1%% in the recent quarter to 14,969%, yielding EPS of $(0.25).

The firm generated $(3.03M) in net cash from operations in the previous quarter, bringing its balance at the close of the quarter to 15.99M%. Net change in cash balance from the preceding period was $11.73M.

Let us look into the charts of the stock:

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

With that, Matinas BioPharma Holdings Inc. reported $22.03M in total assets at the close of the quarter. It recorded debt of 57,352%, which was down/up growing from the previous period.

In the existing quarter, analysts are predicting EPS of $-0.05 from Matinas BioPharma Holdings Inc.. That compares with EPS of $(0.25) in the last quarter.

Coming to earnings, the firm recorded EPS of $-0.42 in the last financial year, while EPS for the current year is anticipated to grow -17.20% over the prior year.

EPS metric is impacted by profits a firm generates in a certain period and the number of due shares in it has in that given period. For the previous quarter where EPS was EPS $(0.25), shares outstanding were 84.6M.

Who owns Matinas BioPharma Holdings Inc.? first, of the firm?s outstanding shares, 64.95M are free float. The firm’s shares sold short are 1.99%, implying a short ratio of 2.21.

As for the title, insiders own 13.90% of the firm, with that ownership moderately being a result of – insider transactions in the previous couple of months. Institutional shareholder ownership in the stock is 1.90%, stemming from 489.14% institutional transactions in the last few months.

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today reported topline data from its Phase 2 safety, tolerability and efficacy study of MAT2203 in women with moderate to severe vulvovaginal candidiasis (VVC). The Phase 2 study achieved its primary endpoint in demonstrating MAT2203 is safe and well tolerated. However, both the clinical and mycological responses for MAT2203 did not meet the Company’s expectations and were below that of fluconazole, the guideline recommended therapy for the treatment of VVC.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.